Lipoprotein(a) apheresis in patients with peripheral arterial disease: rationale and clinical results Norbert WeissUlrich Julius OriginalPaper Open access 15 March 2019 Pages: 39 - 44
Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region Florian Kronenberg ReviewPaper Open access 11 March 2019 Pages: 5 - 12
Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors U. JuliusS. TselminS. R. Bornstein OriginalPaper Open access 05 March 2019 Pages: 45 - 50
Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels V. J. J. SchettlerC. L. NeumannScientific Board of GLAR for the German Apheresis Working Group OriginalPaper Open access 05 March 2019 Pages: 33 - 38
Is lipoprotein(a) a risk factor for ischemic stroke and venous thromboembolism? Alexander Heinrich NaveArnold von Eckardstein OriginalPaper Open access 05 March 2019 Pages: 28 - 32
Lipoprotein(a)—an interdisciplinary challenge U. JuliusS. TselminS. R. Bornstein OriginalPaper Open access 05 March 2019 Pages: 20 - 27
Lipoprotein(a) and mortality—a high risk relationship Reinhard KlingelAndreas HeibgesCordula Fassbender OriginalPaper Open access 05 March 2019 Pages: 13 - 19
Erratum to: The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on V. J. J. SchettlerC. L. NeumannScientific Board of GLAR for the German Apheresis Working Group Erratum 17 July 2017
Editorial Lp(a) – the underestimated cardiovascular risk factor Klaus-Peter Mellwig Editorial Open access 24 February 2017 Pages: 1 - 1
The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on V. J. J. SchettlerC. L. NeumannScientific Board of GLAR for the German Apheresis Working Group OriginalPaper Open access 23 February 2017 Pages: 44 - 49
Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a) P. GrützmacherB. ÖhmC. Kleinert OriginalPaper Open access 23 February 2017 Pages: 22 - 26
Lipoprotein (a) and coronary heart disease – is there an efficient secondary prevention? Klaus-Peter MellwigDieter HorstkotteFrank van Buuren OriginalPaper Open access 23 February 2017 Pages: 18 - 21
Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease Frank van BuurenDieter HorstkotteKlaus Peter Mellwig OriginalPaper Open access 22 February 2017 Pages: 55 - 59
Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies Evelyn OrsóGerd Schmitz OriginalPaper Open access 10 February 2017 Pages: 31 - 37
Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines Reinhard KlingelAndreas HeibgesPro(a)LiFe-Study Group OriginalPaper Open access 09 February 2017 Pages: 38 - 43
Hyperlipoproteinaemia(a) – apheresis and emerging therapies Anja Vogt OriginalPaper Open access 09 February 2017 Pages: 12 - 17
Lipoprotein(a) in nephrological patients Bernd Hohenstein OriginalPaper Open access 08 February 2017 Pages: 27 - 30
PCSK9 targets important for lipid metabolism Rainer SchulzKlaus-Dieter Schlüter OriginalPaper Open access 07 February 2017 Pages: 2 - 11
Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy – successful treatment with lipoprotein apheresis Franz HeiglReinhard HettichCordula Fassbender OriginalPaper Open access 03 February 2017 Pages: 50 - 54
Rehabilitationsstandards für die Anschlussheilbehandlung und allgemeine Rehabilitation von Patienten mit einem Herzunterstützungssystem (VAD – ventricular assist device) Detlev WillemsenC. CordesJ. Glatz OriginalPaper Open access 16 February 2016 Pages: 2 - 49
Geleitwort zu „Rehabilitationsstandards für die Anschlussheilbehandlung und allgemeine Rehabilitation für Patienten mit einem Herzunterstützungssystem (VAD Ventricular Assist Device)“ Hermann Reichenspurner Editorial 16 February 2016 Pages: 1 - 1
Lipoprotein(a)—clinical aspects and future challenges Bilgen KurtMuhidien SoufiJuergen R. Schaefer OriginalPaper Open access 03 March 2015 Pages: 26 - 32
Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects Gerd SchmitzEvelyn Orsó OriginalPaper Open access 24 February 2015 Pages: 21 - 25
Indications for apheresis as an ultima ratio treatment of refractory hyperlipidemias P. GrützmacherC. KleinertB. Öhm OriginalPaper Open access 17 February 2015 Pages: 2 - 7
Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease Franz HeiglReinhard HettichReinhard Klingel OriginalPaper Open access 12 February 2015 Pages: 8 - 13
Extrakardiale Manifestation der Lipoprotein(a)-Erhöhung – Gehäuftes Auftreten von peripherer arterieller Verschlusskrankheit und Stenosen der Arteria carotis Frank van BuurenJulia Alexia SommerKlaus Peter Mellwig OriginalPaper Open access 10 February 2015 Pages: 39 - 45
Lipoprotein(a) – Einfluss auf die kardiovaskuläre Manifestation K.-P. MellwigC. SchattonF. van Buuren OriginalPaper Open access 10 February 2015 Pages: 33 - 38
Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels Volker J. J. SchettlerClass L. NeumannThe German Apheresis Working Group OriginalPaper Open access 05 February 2015 Pages: 14 - 20
Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study Reinhard KlingelAndreas HeibgesCordula Fassbender OriginalPaper Open access 03 February 2015 Pages: 46 - 50
Medikamentöse Therapie bei Frauen – Was gilt es zu beachten? Ursula Ravens OriginalPaper 20 March 2013 Pages: 32 - 37
Der feine Unterschied – Genderspezifische Aspekte psychosozialer Risikofaktoren und Interventionen bei Patienten mit koronarer Herzkrankheit Alexandra BoeseChristoph Herrmann-Lingen OriginalPaper 19 March 2013 Pages: 46 - 51
Genderspezifische Aspekte in der Sekundärprävention der koronaren Herzerkrankung Oskar Mittag OriginalPaper 01 March 2013 Pages: 52 - 56
Gender aspects in patients with angina and unobstructed coronary arteries Peter OngAnastasios AthanasiadisUdo Sechtem OriginalPaper 19 February 2013 Pages: 25 - 31
Sex differences and sex hormone effects in long-QT syndrome: what can we learn from rabbit models? Katja E. OdeningManfred ZehenderMichael Brunner OriginalPaper 19 February 2013 Pages: 14 - 19
Gender and the risk of stroke in atrial fibrillation: impact of old and new anticoagulation regimens Stavros Z. ApostolakisStavros V. Konstantinides OriginalPaper 16 February 2013 Pages: 38 - 45
Risk-treatment paradox in women with symptomatic coronary artery disease Julinda MehilliLamin King OriginalPaper 16 February 2013 Pages: 20 - 24
Genes and hormones: sex differences in myocardial hypertrophy Ute SeelandVera Regitz-Zagrosek OriginalPaper 16 February 2013 Pages: 6 - 13
Lipid apheresis techniques: current status in Germany Peter GrützmacherClaudius Kleinert OriginalPaper Open access 15 May 2012 Pages: 20 - 23
Role of lipid apheresis in changing times Peter Schuff-WernerSebastian FengerPeter Kohlschein OriginalPaper Open access 03 May 2012 Pages: 7 - 14
HELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures Frank van BuurenSven KreickmannKlaus Peter Mellwig OriginalPaper Open access 20 March 2012 Pages: 24 - 30
Current view: indications for extracorporeal lipid apheresis treatment Volker SchettlerC. L. NeumannThe German Apheresis Working Group OriginalPaper Open access 20 March 2012 Pages: 15 - 19
Lipid apheresis: oxidative stress, rheology, and vasodilatation K.-P. MellwigE. PulawskiF. van Buuren OriginalPaper Open access 10 March 2012 Pages: 45 - 49
Fibrinogen/LDL apheresis is a promising rescue therapy for sudden sensorineural hearing loss Martin CanisFranz HeiglMarkus Suckfuell OriginalPaper Open access 28 February 2012 Pages: 36 - 40
Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis Nils EwaldHans-Ulrich Kloer OriginalPaper Open access 28 February 2012 Pages: 31 - 35